<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759495</url>
  </required_header>
  <id_info>
    <org_study_id>CORRIDA LIFE</org_study_id>
    <nct_id>NCT04759495</nct_id>
  </id_info>
  <brief_title>Is Real-time CGM Superior to Flash Glucose Monitoring in Real Life Study (CORRIDA LIFE)</brief_title>
  <official_title>Comparison of CGM in Non-randomised Real Life Study of Real-time and Intermittently Scanned Systems in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigator's study is to compare real-time continuous glucose monitoring&#xD;
      (rt-CGM) and flash glucose monitoring (FGM) in adult patients with Type 1 Diabetes (T1D) in&#xD;
      real life practice during 24 weeks of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glycated haemoglobin (HbA1c)</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Differences between HbA1c values in the Run in period and after 12 month of follow-up and differences of HbA1c between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time in hypoglycemic ranges</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>&lt;3.9 mmol/L [70 mg/dl] and &lt;3.0 mmol/L [54 mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time in target ranges</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>3.9-10.0 mmol/L [70-180 mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time in hyperglycemic ranges</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>&gt;10.0 mmol/L [180 mg/dl] and &gt;13.9 mmol/L [250 mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycemic variability</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Expressed as the standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sensor glucose concentration</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Measured by rtCGM or FGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycaemia</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Requiring third-party assistance to treat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe ketoacidosis</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Skin reaction, infection or hematoma reported by patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>rtCGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)</intervention_name>
    <description>rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.</description>
    <arm_group_label>rtCGM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)</intervention_name>
    <description>FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.</description>
    <arm_group_label>FGM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with T1D naive to rt-CGM and FGM&#xD;
&#xD;
          -  Type 1 diabetes for &gt; 1 year&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  CSII without automatic functions or MDI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous rtCGM or FGM use&#xD;
&#xD;
          -  treatment with insulin pump with automatic functions&#xD;
&#xD;
          -  severe noncompliance&#xD;
&#xD;
          -  known severe diabetic retinopathy and/or macular edema&#xD;
&#xD;
          -  lactation, pregnancy, or intending to become pregnant during the study&#xD;
&#xD;
          -  a condition likely to require MRI&#xD;
&#xD;
          -  use of acetaminophen-containing medication&#xD;
&#xD;
          -  unwillingness to use the study device for &gt;70% of time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Soupal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University, Prague</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Hásková A, Radovnická L, Petruželková L, Parkin CG, Grunberger G, Horová E, Navrátilová V, Kádě O, Matoulek M, Prázný M, Šoupal J. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care. 2020 Nov;43(11):2744-2750. doi: 10.2337/dc20-0112. Epub 2020 Aug 28.</citation>
    <PMID>32859607</PMID>
  </reference>
  <reference>
    <citation>Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Review.</citation>
    <PMID>24526393</PMID>
  </reference>
  <reference>
    <citation>Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, Škrha J, Svačina Š, Prázný M. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016 Sep;18(9):532-8. doi: 10.1089/dia.2016.0171. Epub 2016 Aug 2.</citation>
    <PMID>27482825</PMID>
  </reference>
  <reference>
    <citation>Šoupal J, Petruželková L, Grunberger G, Hásková A, Flekač M, Matoulek M, Mikeš O, Pelcl T, Škrha J Jr, Horová E, Škrha J, Parkin CG, Svačina Š, Prázný M. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. Diabetes Care. 2020 Jan;43(1):37-43. doi: 10.2337/dc19-0888. Epub 2019 Sep 17.</citation>
    <PMID>31530663</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975.</citation>
    <PMID>28118453</PMID>
  </reference>
  <reference>
    <citation>Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krӧger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018 Mar;61(3):539-550. doi: 10.1007/s00125-017-4527-5. Epub 2017 Dec 23.</citation>
    <PMID>29273897</PMID>
  </reference>
  <reference>
    <citation>Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016 Nov 5;388(10057):2254-2263. doi: 10.1016/S0140-6736(16)31535-5. Epub 2016 Sep 12.</citation>
    <PMID>27634581</PMID>
  </reference>
  <reference>
    <citation>Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, Hermanns N. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018 Apr 7;391(10128):1367-1377. doi: 10.1016/S0140-6736(18)30297-6. Epub 2018 Feb 16.</citation>
    <PMID>29459019</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Jan Soupal, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Continuous Glucose Monitoring</keyword>
  <keyword>Flash Glucose Monitoring</keyword>
  <keyword>Hypoglycaemia</keyword>
  <keyword>Time in Range</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

